**Quantifying drivers of antibiotic resistance in humans:
A systematic review**

Anuja Chatterjee MSc^{1*}, Maryam Modarai PhD¹, Nichola R Naylor MSc¹, Sara E Boyd MRCP^{7,2,1},
Rifat Atun FRCP^{3,1}, James Barlow PhD⁴, Alison H Holmes FMedSci^{1,2}, Alan Johnson PhD^{5,1}, Julie V
Robotham PhD^{6,1}

1. National Institute for Health Research, Health Protection Research Unit in Healthcare Associated
Infection and Antimicrobial Resistance, Imperial College London, Hammersmith Campus, W12 0NN.
United Kingdom

2. Imperial College London Healthcare NHS Trust, London. United Kingdom

3. Department of Global Health and Population and Department of Health Policy and Management,
Harvard University, 651 Huntington Avenue, FXB 634, Boston, MA 02115. USA

4. Centre for Health Economics & Policy Innovation, Imperial College Business School, South
Kensington Campus, SW7 2AZ. United Kingdom

5. Department of Healthcare-Associated Infections and Antimicrobial Resistance, National Infection
Service, Public Health England, London NW9 5EQ. United Kingdom

6. Modelling and Economics Unit, National Infection Service, 61 Colindale Avenue, Public Health
England, NW9 5EQ. United Kingdom

7. Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical
Pharmacology, University of Liverpool, Liverpool, L69 3GE

*Correspondence to: A. Chatterjee, 8th Floor, Commonwealth Building, Imperial College London,
Hammersmith Hospital, Du Cane Road, W12 0NN. Email: ac6315@ic.ac.uk.
Phone: +447817543458

Summary (150 words)

A horizon scan linking the quality/quantity of data reported on the drivers of antibiotic resistance (AR) in humans arising from the human, animal and environment reservoirs is needed to mitigate risks of AR. We adopted a systematic reviewing methodology using a “One Health” approach to survey the key drivers in humans.

565 studies from 2,819 title/abstracts were identified after two sets of reviewers selected studies from Embase, MEDLINE, and Scopus (2005-2018), ECDC, CDC, and WHO (One Health data). Quality assessment was carried out in line with Cochrane recommendations.

Prior antibiotic exposure, underlying disease, and invasive procedures were the key risk factors identified from the 88 risk factors retrieved. Studies primarily reported a 2 to 4-fold increased risk of AR due to these risks identified. Food/water transmission were frequently quantified from the animal/environment-reservoirs respectively.

Uniformly quantifying relationships between risk factors will help researchers better understand the cycle of AR in humans.

Introduction

Antibiotic resistance (AR) is a growing, multifaceted health concern, resulting in increased morbidity, mortality for patients, and financial costs for healthcare systems¹. Antibiotic-resistant bacteria (ARB) are found in humans, diverse animal hosts and in the environment. Each of these contributes to the epidemiology of AR²⁻⁵. (See Panel A)

Reviews, meta-analyses and observational studies determining drivers of the emergence and transmission of AR have been published^{2,3,6-8}. Antibiotic use and failure to apply effective infection prevention and control measures are well established as key drivers of AR^{9,10}. However, given the recent international focus on reducing AR¹¹ and a greater attention to modelling the risk of the “One Health” impact on humans (Panel A)⁴, there is a need for detailed knowledge of the reservoirs and emerging cross-reservoir risk factors of AR. In particular, we need to broaden our understanding of the natural selection and transmission patterns of ARB which currently threaten healthcare delivery, particularly for patients undergoing invasive procedures such as surgery or those receiving immunosuppressive therapies¹.

In an attempt to depict the links between the human, animal and environmental reservoirs of antimicrobial resistance (AMR), a systems map was published by the UK Department of Health (DH), as part of the UK’s national AMR strategy¹². However, these maps were created using expert opinion rather than literature sources and the links were not quantified¹². There has been no systematic retrieval or quality assessment of evidence for the risk factors for AR in humans, nor the quantification of these risk factors among major bacterial species across the three reservoirs. A synthesis of evidence is urgently required to aid policy-level decision making, ensuring that strategies to minimise the burden of AR can be appropriately prioritised.

Therefore, the aim of this research was to conduct a survey of the evidence available on the quantified risk factors of AR in humans by systematically retrieving and reviewing this evidence and generating an overview of the quality and quantity of these studies. In addition, this data was used to create an up-to-date map quantifying the drivers identified as part of this horizon scan for AR to compliment and extend the UK AMR systems map¹².

Methods

Search strategy and selection criteria

The PRISMA protocol was followed to conduct this systematic review¹³. Quantified evidence on the risk factors from human, animal and environment, which result in AR in humans, were identified. EMBASE, MEDLINE(R) In-Process & Other Non-Indexed Citations, MEDLINE(R) were searched via Ovid, and Scopus was searched separately. Only full text articles published in English between 01.01.2005 - 14.02.2018 were included. Grey literature quantifying the most recent primary data on One health from the European Centre for Disease Prevention and Control (ECDC) and Centers for Disease Control and Prevention (CDC) and World Health Organisation (WHO) websites were searched. Additional meta-analyses studies on risk factors of AR in humans were also included from Pubmed (Section II in supplementary web appendix) to capture any missed risk factors not identified from the primary data search in Ovid and Scopus. Population, Intervention, Comparator, Outcome, and Study design (PICOS) criteria were utilised for inclusion/exclusion decisions. (Table S1). No studies were excluded based on the quality of the papers or the sample size. From the included studies, study characteristics and outcomes were extracted into a pre-specified Data Extraction Table (in Microsoft Excel© 2016) (Table S2).

Panel A: Study Terminology

- ❖ Antibiotic resistance is defined as bacteria with acquired or inherent resistance to at least 1 antibiotic.
- ❖ Community setting includes a setting outside of a healthcare environment such as households. The animal and environment reservoirs are included within this setting.
- ❖ Environmental reservoir includes non-meat related food (e.g. vegetables), soil or water related sources.
- ❖ Healthcare setting includes hospitals and long-term care facilities.
- ❖ Invasive procedures include procedures carried out at a healthcare setting, for example, use of indwelling devices such as catheterisation or intubation.
- ❖ Multidrug resistant bacteria are defined as bacteria with acquired resistance to at least 3 drugs from different classes of antibiotics⁷⁷.
- ❖ ESBL-Bacteria have been separately coded to MDR-B despite ESBL-B being a type of MDR-B since there has been a surge of international concern around these organism types, and a large number of papers were also identified for this group of organisms.
- ❖ One Health is defined as the inter-relationship between the human, animal and environmental reservoirs, and how these relationships impact AR in humans.
- ❖ 'Risk factor' is used as a proxy term for drivers of antibiotic resistance.

"A risk factor is any attribute, characteristic or exposure of an individual that increases the likelihood of the individual:

i) being colonised/infected by antibiotic-resistant bacteria, or

ii) transmitting such types of bacteria to another individual or the surrounding environment"

149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168

Study selection and quality assessment

Four reviewers conducted the review and applied the PICOS criteria to select the relevant articles. One reviewer (AC) assessed all title/abstracts (T/A) and full texts (FTs) for inclusion, a second reviewer (MM) assessed 50% of all T/A and FTs, and a third (SEB) and fourth reviewer (NRN) assessed 25% each of the remaining T/A and FTs titles. In the event of a disagreement, a senior researcher (JR), independent of the four reviewers, was consulted. After final study selection, duplicates were removed by identification of the same Ovid ID alongside hand searching. Following the identification of the FTs, one reviewer (AC) conducted the quality assessment of all papers and a second reviewer (MM) independently checked 12 randomly selected articles. Quality was determined using the Critical Appraisal Skills Programme (CASP) based on Cochrane guidelines^{7,14–16}, in which selection, information and confounding bias were assessed. Reporting bias criteria were defined in line with methodology utilised in a recently published meta-analysis on observational studies in AR¹⁴. (Supplementary Section III)

The full study protocol was prospectively registered with PROSPERO (CRD42016038450).

Panel B: Search strategy*

Microbial-drug-resistan\$.tw. or ((microb\$ or antimicrob\$ or anti-microb\$ or anti microb\$) adj2 resist\$).tw. or ((antibiot\$ or anti-biot\$ or anti biot\$) adj2 resist\$).tw. or Multidrug resistan\$.tw. or multidrug-resistant bacteria.ti,ab. or exp Drug Resistance, Microbial/ or (superbug\$ or super-bug\$ or super bug\$).tw. or Superinfection/ or (resistant adj2 infection\$).ti,ab.

AND

(emergence or spread or outbreak* or prevalence or incidence or acquisition).tw. or exp cross infection/ or exp infectious disease transmission, patient-to-professional/ or exp infection control/ or (patient-to-patient adj2 transmission).tw. or exp infectious disease transmission, professional-to-patient/ or exp disease transmission, infectious/ or infectious disease transmission.tw. or disease transmission.tw. or ((transfer or transmission) adj2 resist\$).ti,ab. Or contamination.tw. or ((bacterial pathogen* and coloni\$) or Coloni?ation).tw. or (resist\$ adj2 develop\$).tw

AND

((cause or drive or driving or driver or predictor or determinant or determinants or mechanism) adj4 resist\$).ti,ab. or exp risk factor/ or risk factor.ti,ab. or risk score.tw. or infection reduction.tw. or infection risk.tw. or risk assessment.tw. or risk benefit analysis.tw. or (antibiotic adj2 (use\$ or usage or consum\$ or prescri\$)).tw. or (food chain or (water and (supply or quality)) or animal husbandry or food producing animal or food-producing animal).tw. or (poor adj2 hygiene).tw. or (poor and (infection control or infection-control)).tw.

AND

(risk ratio or relative risk or odds ratio or hazard ratio or statistical correlation or correlation coefficient or statistical analysis or multivariable analysis or regression).tw. or epidemiology studies.ti,ab. or exp odds ratio/ or exp epidemiologic studies/ or exp Statistics as Topic/ or exp Epidemiologic Study Characteristics as Topic/ or estimat\$.tw. or quantif\$.tw.

Limits: English language, full texts, 2005 onwards

Excludes: book or book series or chapter or conference abstract or editorial or erratum or letter or note

exp: Explosion terms (in Embase) /MESH terms (in Medline)

*Search strategy developed with medical librarian

185
186
187
188
189
190
191
192
193
194
195
196
197
198
199

Data analysis

Quantitative evidence which included statistically significant results and point estimates for the risk factors of AR from the human reservoir or AR prevalence levels from food or water sources as potential transmission routes into the human reservoir were extracted. Only statistically significant risk factor estimates based on p-values were extracted from the human reservoir studies. If there were discrepancies between what was stated as statistically significant and reported p-values, then these results were not extracted. For the multivariate sub-analysis, only complete results with significant p-values, complete confidence intervals and sample size were included. If odds ratios were reported as significant with confidence intervals that included 1, these results were excluded. In addition, these result discrepancies were captured under reporting bias during the quality assessment stage.

Due to limited quantified evidence from the animal and environment reservoirs, prevalence levels were extracted (e.g. Prevalence of resistant bacteria from retail meat or prevalence of resistant genes from water sources as proxies for indirect transmission routes into the humans reservoir). Following data extraction, all data was imported into R version 3.4.1 and analysed using the 'dplyr' package.

A meta-analysis was deemed inappropriate given the heterogeneity in terms of patient population, definition of outcomes and risk factors under study. Mean quality assessment scores were reported with their respective standard deviation (SD) on a range from 0-1. Due to cell structure differences, compared to Gram-positive bacteria, Gram-negative bacteria are more resistant to antibiotics, thus, the results of the review were often split based on this classification criterion.

The drivers of AR map and risk factor grouping

All risk factor estimates were coded based on their study-specific definitions, for example prior antibiotic use, with or without underlying disease (Table S4). Based on classification methods utilised in previous AR related meta-analyses¹⁷⁻¹⁹ and risk factor framework studies in medical literature²⁰⁻²², the themes arising from these risk factors were split into the following risk domains: 1) Patient clinical history: Includes underlying disease or comorbidities ; 2) Demographics : age, gender, ethnicity; 3) Healthcare factors: includes various procedure related contact with hospital / intensive care unit / nursing home/ long-term care facility/ outpatient services or hospital environment related factors ; 4) Antibiotic use related factors: includes prior history of antibiotic use or impact of antibiotic use in animals on humans 5) Community-level factors: where risk factors were neither related to healthcare contact, nor due to the clinical condition of the patient. Cross-reservoir drivers such as meat related food transmission, occupational and domestic exposure to animals from the animal reservoir, or water and vegetable related food transmission from the environment reservoir were included within this community domain. Notably, these domains are not mutually exclusive, and the potential for causal relationships across and between these domains are discussed within the discussion section, as identifying such links between the domains was not within the scope of this review.

To be able to report on all the risk factors we had identified in the review (see Table S4 in the supplementary index for a full list of risk factors), creation of these domains was needed to enable description of the overall evidence on risk factors of AR impacting humans in a holistic way.

Results

In total 2,819 title and abstracts were screened. The PRISMA flow diagram (Figure 1) describes the selection process.

*Figure 1: PRISMA flow diagram**

**Please refer to the PICOS exclusion criteria in supplementary appendix for further explanation (Table S1)*

[Figure supplied in PDF to be inserted here.]

1,883 title/abstracts were excluded, following which 936 full text articles were reviewed, out of which 371 articles were ineligible for inclusion. In total, 565 full text articles were included for data extraction and quality assessment. Out of the 565 full text articles, 527 were primary studies and 38 were meta-analysis studies.

Study population and reservoirs

Overall

Out of the primary studies, a total of 469 studies (89%) were reporting on risk factors from within the human reservoir and 58 studies (11%) were reporting on cross reservoir risk factors on the relationship between the animal or environment and human reservoir (Figure 2). Four meta-analyses studies pooled quantified risk factors from the animal and human reservoir. No meta-analysis was identified for the overlap between environment and human reservoir.

The top three resistant bacteria under study were multidrug-resistant bacteria (excludes extended spectrum beta-lactamase-producing bacteria) (MDR-B: 20% (104 studies)), meticillin-resistant *Staphylococcus aureus* (MRSA: 19% (98 studies)), and antibiotic-resistant *Escherichia coli* (R-EC: 15% (78 studies)) (Table S5). Most (42% (16) meta-analysis studies quantified risk factors of MRSA. The full list of included articles and their study characteristics are reported in Table S2. Of the 469 human-only studies, 65% related to an adult population, and 8% did not explicitly specify age groups.

Cross reservoir

Antibiotic-resistant *Escherichia coli* (R-EC) was the most frequently studied organism (38% (22 studies)) among cross-reservoir drivers.

The potential transmission routes from the animal to human reservoir were either via food sources^{25,27-46}, or from animal contact^{24,36,45-52}. In contrast, environment to human reservoir routes were water^{39,46,53-59} and vegetable related sources⁶⁰. The highest reported resistant isolates out of all the cross reservoir risk factors were from broiler meat which were ESBL-EC samples (43% (resistant isolates: 36,241) followed by meat from turkey which were R-EC samples (25% (1714 resistant isolates).

Study types and quantification techniques

The majority of studies (55% (312)) adopted a cohort design, while 26% (146) adopted a case-control methodology. A cross-sectional, prevalence or time-series study approach was used for 12% (65) (Figure SF1), and 7% (38) were meta-analyses. There were no meta-analyses that included links between human and environmental reservoirs. In the human reservoir, an odds ratio (OR) was frequently used to quantify the risk factors; incidence and prevalence rates were the common outcome measures in the other reservoirs (Figure SF2). The majority of studies were based in Organisation of Economic Cooperation and Development (OECD) countries (76% (404)), whilst 19% (99) were based in non-OECD countries, and 1% (3) were global. The meta-analyses studies primarily (92% (35) had a global scope.

Study quality

Quality assessment showed that overall there was a low risk of bias among the 527 observational studies (Table S2, Figure SF3). 56% (312) of the observational studies were reported well; failure to report study design (18% (96)) and baseline characteristics (13% (71)) were the commonest reasons for studies to score poorly (Panel 1: Figure SF3). However, around 30% of the studies were subject to confounding bias (34% (177)) and information bias (29% (155)) when it came to identification of exposure variables (Panel 2: Figure SF3). The meta-analyses studies were primarily of good quality according to the PRISMA assessment tool. (Mean: 0.90 (0.09))

Primary studies focusing on the human reservoir showed on average the highest quality score ratings (mean: 0.66 (SD: 0.18), indicating a lower risk of bias. In comparison, the other reservoirs had a higher risk of bias (mean 0.33-0.47 (SD: 0.16-0.17)) (Figure 2).

Figure 2: Reservoir specific number of studies, quality and top risk factors
[Figure supplied in PDF to be inserted here.]

Risk factors

The 527 primary studies were utilised to construct an AR drivers' map (Figure 3). Most studies quantify links between antibiotic use (56%), healthcare contact (53%) or patient clinical history (47%), and AR in humans. (Figure 3).

Fewer studies reported risk factors from the community factors (20%) and patient demographics (18%) domains.

The studies from the healthcare factors domain were on average of better quality (0.68 (0.18)) compared to studies reporting community factors (0.46 (0.18)). (Figure 4)

A detailed table with the five domains and their respective risk factors are presented in Table S4 along with the number of studies retrieved and their respective quality scores.

Figure 3: Percentage of studies quantifying the drivers of antibiotic resistance in humans N = 527 studies

Please note the bubble size represents the percentage of studies out of the total number of primary studies (n = 527) for both the risk domains and their individual risk factors.

For ease of presentation and clarity only the top 5 risk factors from the individual risk domains have been presented - these percentages may not add up to the total risk domain percentage. A singular study may report a variety of risk factors across all of these domains so there will be duplicate studies present in the domains. The distance between the bubbles are not indicative of anything.

[Figure supplied in PDF to be inserted here.]

Figure 4: Quality of studies quantifying the drivers of antibiotic resistance in humans
 [Figure supplied in PDF to be inserted here.]
 Bubble size represents mean quality score

Sub-analysis of outcomes reported across the domains

The risk factors identified in the review were reported for various outcomes of AR in humans. Figure 5 describes the type of outcomes and number of studies extracted from each risk domain. AR-related infections were most frequently reported, followed by colonisation with ARB across all studies. Gram-negative bacteria were the most frequently estimated resistant bacteria across all outcomes with the exception of carriage of ARB, where Gram-positive bacteria predominated. In terms of risk domains driving the respective outcomes, healthcare contact was most frequently reported to result in AR-related infections (64% (113 studies)), whereas patient clinical history was most frequently reported to result in colonisation with ARB. Antibiotic use was reported to result in acquisition (57% (48 studies)), emergence (66% (40 studies) or carriage (55% (31 studies) of AR. In contrast, community-level factors were driving indirect routes arising from cross-reservoir transmission. (45 studies)

The quality of the studies reporting on infection (mean: 0.65 S.D:0.2) and colonization (mean: 0.63, S.D: 0.2) were better with lower risk of bias compared to the transmission related studies (mean: 0.45 S.D: 0.23).

Majority (39% (15 studies) of the meta-analyses studies quantified AR outcomes for infection, followed by colonisation (21% (8 studies).

Figure 5: Overview of the risk factor domains stratified by outcomes[†] of AR. Panel A: Total number of studies split based on type of outcome for AR across the five risk domains; Panel B: Total number of studies split based on type of outcome for AR and bacteria type
 [Figure supplied in PDF to be inserted here.]

*Mixed includes estimates from resistant genes or studies reporting pooled results for Gram-positive and Gram-negative bacteria

Please note: 1) Studies reporting on resistant genes have not been presented in Panel B – this is the reason behind fewer studies in e.g. transmission outcome in Panel B compared to Panel A,

2) one study may report on both Gram-positive and Gram-negative bacteria types, this overlap is the reason behind e.g. higher infection studies in Panel B compared to Panel A

†Infection: ARB causing infection; Colonised: Colonised but not infected by ARB; Acquisition: Directly acquiring ARB (including infection) from another host or the surrounding environment; Emergence: Determinants, predictors, factors increasing prevalence of antibiotic resistance in humans; Carriage: Includes nasal / faecal / skin carriage; Indirect transmission: Indirect acquisition routes which facilitate the transfer of ARB from one host to another host (human to human / animal to human) or from environment to host (and vice versa). Prevalence of ARB from uncooked/cooked food sources as well as water sources have also been used as proxies for these routes; Other: includes combination of 'colonisation/infection/acquisition', 'transmission/carriage' or specified as a 'risk factor of resistant organism'

Note: Transmission, emergence or acquisition routes are often difficult to determine clinically, in particular from retrospective studies. These terms have been directly elicited from the studies giving rise to i) overlap between these outcomes and ii) heterogeneity across their study specific definitions.

Sub-analysis of odds ratio estimates reported from multivariate analysis results and meta-analyses

Up until this point the drivers of AR were expressed in terms of the quantity and quality of evidence extracted. To determine the strength of the evidence, a sub analysis was conducted of the odd ratio (OR) from independent risk factors reported from studies which conducted a multivariate analysis (does not include the meta-analyses results). Within this analysis, only studies reporting complete datasets (i.e. number of cases, OR with significant confidence intervals) were included.

(Table S6 provides the OR ranges elicited from this analysis along with the number of studies and their quality) Table 1 provides the percentage of studies reporting the specified OR ranges split for

the top two outcomes and for Gram-positive and Gram-negative bacteria. Risk of AR due to antibiotic use and community level factors had wide OR ranges, compared to the other domains. Table 1 displays the OR distribution, where the odds of ARB in humans was primarily reported to be between 2 to 4 fold higher due to the impact of the different risk domains. The distribution from the meta-analyses studies in Table 2 shows that odds of AR in humans are primarily reported to be between 2 to 3 fold higher given these risk domains. A larger number of studies reported odds of AR due to healthcare contact risk between 1 and 2. Whereas, the number studies reporting on odds for AR due to antibiotic use were spread between 2 and 4.

Table 1: Percentage of studies per domain reporting specified odds ratio ranges* from the multivariate analysis results

Overall	OR >1 - <2	OR ≥2 - <3	OR ≥3 - <4	OR ≥4 - <5	OR ≥5 - <6	OR ≥6 - <7	OR ≥7 - <8	OR ≥8 - <9	OR ≥9 - <10	OR ≥10 - <12	OR ≥12 - <14	OR ≥14 - <16	OR ≥16 - <18	OR ≥18 - <20	OR ≥20
Patient clinical history (n = 147)	16%	34%	22%	15%	7%	8%	8%	3%	5%	3%	3%	4%	2%	3%	5%
Health care contact (n = 184)	24%	35%	27%	20%	12%	7%	6%	4%	3%	5%	4%	2%	4%	1%	9%
Antibiotic use (n = 189)	15%	32%	20%	13%	16%	7%	10%	3%	4%	5%	7%	4%	1%	2%	8%
Community level factors (n = 34)	21%	29%	29%	12%	12%	9%	3%	9%	0%	3%	3%	3%	3%	6%	15%
Patient demographics (n = 54)	28%	37%	19%	11%	6%	2%	4%	0%	2%	2%	4%	4%	0%	0%	2%
Comparison of top two outcomes from the review															
Infection	OR >1 - <2	OR ≥2 - <3	OR ≥3 - <4	OR ≥4 - <5	OR ≥5 - <6	OR ≥6 - <7	OR ≥7 - <8	OR ≥8 - <9	OR ≥9 - <10	OR ≥10 - <12	OR ≥12 - <14	OR ≥14 - <16	OR ≥16 - <18	OR ≥18 - <20	OR ≥20
Patient clinical history (n = 53)	19%	36%	17%	15%	9%	6%	8%	4%	6%	4%	6%	0%	2%	0%	6%
Health care contact (n = 73)	26%	30%	27%	26%	12%	3%	5%	3%	5%	10%	4%	1%	3%	0%	8%
Antibiotic use (n = 69)	6%	32%	20%	13%	17%	7%	9%	1%	4%	6%	12%	4%	0%	0%	6%
Community level factors (n = 7)	14%	14%	29%	0%	0%	0%	14%	0%	0%	0%	0%	0%	0%	14%	14%
Patient demographics (n = 18)	33%	33%	22%	6%	6%	0%	0%	0%	0%	6%	0%	0%	0%	0%	6%
Colonisation	OR >1 - <2	OR ≥2 - <3	OR ≥3 - <4	OR ≥4 - <5	OR ≥5 - <6	OR ≥6 - <7	OR ≥7 - <8	OR ≥8 - <9	OR ≥9 - <10	OR ≥10 - <12	OR ≥12 - <14	OR ≥14 - <16	OR ≥16 - <18	OR ≥18 - <20	OR ≥20
Patient clinical history (n = 40)	15%	33%	30%	18%	8%	3%	10%	8%	10%	5%	0%	15%	0%	3%	8%
Health care contact (n = 39)	23%	36%	21%	15%	15%	15%	5%	3%	3%	3%	3%	0%	8%	0%	13%
Antibiotic use (n = 40)	23%	38%	20%	5%	15%	0%	15%	8%	0%	8%	3%	3%	3%	3%	10%
Community level factors (n = 12)	25%	25%	50%	17%	8%	25%	0%	8%	0%	8%	0%	8%	0%	8%	8%
Patient demographics (n = 16)	13%	44%	13%	13%	13%	6%	6%	0%	6%	0%	13%	6%	0%	0%	0%
Comparison of Gram-positive and Gram-negative bacteria type															
Gram-positive	OR >1 - <2	OR ≥2 - <3	OR ≥3 - <4	OR ≥4 - <5	OR ≥5 - <6	OR ≥6 - <7	OR ≥7 - <8	OR ≥8 - <9	OR ≥9 - <10	OR ≥10 - <12	OR ≥12 - <14	OR ≥14 - <16	OR ≥16 - <18	OR ≥18 - <20	OR ≥20

Patient clinical history (n = 50)	18%	36%	26%	12%	6%	10%	8%	4%	2%	6%	0%	6%	0%	0%	6%
Health care contact (n = 52)	27%	42%	25%	6%	12%	0%	4%	0%	4%	0%	4%	4%	2%	0%	10%
Antibiotic use (n = 42)	17%	26%	21%	17%	7%	7%	5%	5%	5%	5%	2%	7%	0%	0%	5%
Community level factors (n = 13)	23%	38%	31%	23%	8%	8%	0%	15%	0%	0%	0%	0%	0%	8%	15%
Patient demographics (n = 23)	35%	30%	17%	0%	4%	0%	4%	0%	4%	0%	0%	9%	0%	0%	4%
Gram-negative	OR >1 - <2	OR ≥2 - <3	OR ≥3 - <4	OR ≥4 - <5	OR ≥5 - <6	OR ≥6 - <7	OR ≥7 - <8	OR ≥8 - <9	OR ≥9 - <10	OR ≥10 - <12	OR ≥12 - <14	OR ≥14 - <16	OR ≥16 - <18	OR ≥18 - <20	OR ≥20
Patient clinical history (n = 88)	15%	27%	24%	15%	6%	8%	8%	2%	7%	2%	6%	3%	2%	3%	6%
Health care contact (n = 111)	22%	31%	24%	22%	14%	11%	8%	5%	4%	6%	5%	1%	5%	2%	8%
Antibiotic use (n = 130)	15%	31%	20%	12%	18%	7%	11%	3%	3%	5%	9%	2%	1%	2%	9%
Community level factors (n = 19)	16%	26%	26%	5%	11%	5%	5%	5%	0%	0%	5%	5%	5%	0%	16%
Patient demographics (n = 27)	19%	48%	19%	15%	0%	0%	4%	0%	0%	4%	7%	0%	0%	0%	0%

*Blue to red scale represents the highest to lowest reported odds ratio using the number of studies as the measure of frequency (Highest reported = 100% and least reported = 0%)

Please note: Since some studies would report multiple odds ratios for multiple factors within each domain there are duplicate studies and the individual rows will add up to >100%.

Table 2: Percentage of studies per domain reporting specified odds ratio ranges* from the meta-analyses studies

Meta-analyses studies (n = 22)*	OR >1 - <2	OR ≥2 - <3	OR ≥3 - <4	OR ≥4 - <5	OR ≥5 - <6	OR ≥6 - <7	OR ≥7 - <8	OR ≥8 - <9	OR ≥9 - <10	OR ≥10 - <12	OR ≥12 - <14	OR ≥14 - <16
Patient clinical history (n = 11)	27%	73%	9%	9%	0%	18%	9%	9%	0%	0%	9%	9%
Health care contact (n = 12)	58%	50%	25%	25%	17%	0%	0%	0%	0%	0%	8%	0%
Antibiotic use (n = 15)	27%	53%	47%	40%	7%	7%	7%	7%	0%	7%	13%	0%
Patient demographics (n = 2)	50%	50%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

*Out of 38 meta-analyses studies, 22 reported Odds ratio which were included in this analyses to maintain a measure of comparison across the primary and meta-analyses studies.

OR: Odds ratio, OR > 16 were not reported in any of the estimates extracted from the meta-analyses, No odds ratios reporting on community level factors were identified from the meta-analyses

Blue to red scale represents the highest to lowest reported odds ratio using the number of studies as the measure of frequency (Highest reported = 100% and least reported = 0%)

Please note: Since some studies would report multiple odds ratios for multiple factors within each domain there are duplicate studies and the individual rows will add up to >100%.

Discussion

This review is aimed at providing an evidence-base for the drivers of AR across the human, animal and environment reservoirs. Understanding the underlying epidemiology of AR is an important step towards the formulation of interventions to control its emergence and transmission in humans. The review found that the largest quantified drivers of AR evidence were from within the human reservoir, with little evidence supporting a direct relationship from the cross-reservoir drivers. Among this evidence, the impact of the animal reservoir on humans was the most frequently studied aspect. Minimal evidence exists to support the environment as a common transmission route to the human reservoir. Evidence for cross-reservoir drivers were primarily from cross-sectional and prevalence studies, where methodological limitations such as greater selection, misclassification and confounding bias reduced their reliability. Such types of bias are usually avoided within well-conducted, cohort and case control studies.

This review describes five risk factor domains of AR in humans. Based on the results from the top three risk factors, determined by the frequency and the quality of the quantified evidence, the review finds underlying disease, antibiotic use and invasive procedures in healthcare settings as the risk factors with the most supporting evidence. The majority of case-control and cohort studies collected data on patient characteristics in hospitals. This suggests the feasibility of retrospectively accessing hospital records to assess potential risk factors. In contrast, the risk factors from the community domain are less frequently included in case-control and cohort study protocols. This suggests that either it is less feasible to collect this data or investigators do not feel they merit inclusion when designing these studies

This review highlights three key gaps in our understanding of the drivers of AR in humans. Firstly, there is a lack of studies investigating causal relationships amongst the risk factor domains and reservoirs. Instead, well-established risk factors such as prior antibiotic exposure and invasive procedures during healthcare contact have been the emphasis of most studies investigating risk factors for AR in humans. The lack of evidence in other areas, for example of risks across cross reservoirs, may not necessarily be indicative of the lack of risk, and the numeric load of evidence should be interpreted with caution.

Secondly, local-level factors correlated with the increase of AR from hospital settings are underrepresented in literature. For example, the impact of scarce resource allocation on staff to patient ratio⁶¹, infection control practices⁶², the role of inter-staff transmission of pathogens, and patient isolation rates^{63,64} cannot be determined from the current literature. At the time of the review, only one meta-analysis reported the impact of prior room occupation on increased risk of AR⁶⁵.

Thirdly, methodologically rigorous studies capturing community-level risk factors are limited. These include impact of environment-related transmission, primary care conditions (e.g. GP contact hours/availability)⁶⁶, impact of education, income, food source, household size, or influence of ethnicity on travel patterns and on health-related behaviour.

Based on these research gaps, the following suggestions for future research can be made. Inclusion of the risk factor domains framework from this review within standardised data collection protocols for AR risk factor studies would ensure inclusion of not only clinical characteristics but also community and hospital-specific characteristics to rule out their confounding effects. Repeated quantification and focus on established risks may in turn lead to more studies being conducted in these similar established risk areas rather in entirely novel areas. There is a need for in depth qualitative research to help justify exploration of underlying factors and raise the profile of certain understudied areas. Thus to further highlight local level risk factors, studies could incorporate qualitative techniques such as surveys and interviews⁶⁷ to support the quantified data from hospital patient records from the retrospective studies.

Given the highly variable outcomes, along with variable individual outcome definitions (e.g. carriage of or acquisition of resistant bacteria), identified from the data extraction in Figure 5, there is a need for clarity and uniformity of these definitions across the field of AR. This would serve to improve granularity and enhance understanding of the methods of transmission or emergence to, in turn, aid efficacy of interventions targeted towards AR in humans

Some limitations of this review should be noted. Firstly, the data extraction and quality assessment was conducted by one reviewer, which may have led to discrepancies in data collection and analysis. All measures have been taken by double checking of data extractions and conducting stress tests when coding the data to limit any discrepancies. The authors (of the studies which were included in this review) were not contacted to clarify the data extractions and should be considered a limitation of this review. The quality assessment was randomly checked by a second reviewer to minimise any bias.

Secondly, due to the recent surge of publications related to AR and the broad search terms which did not use drug-bug combinations as search strings, and the language restriction, this review will not have identified all risk factor studies across all drug-bug combinations and settings. However, the meta-analyses search in Pubmed which utilized the drug-bug combinations from the WHO's antibiotic priority list for the search terms should minimise the risk of missed risk factors

Thirdly, better quality and greater quantity of evidence was retrieved from studies specific to the human reservoir. The key risk domains: antibiotic use, healthcare contact and patient history, were studied to a greater extent possibly due to them being easier to study in terms of data availability from healthcare records and limited resources that are required to conduct retrospective analysis on such data. As a result, there is potential publication bias towards retrospective studies using hospital data to determine risk factors of AR in humans.

Last of all, the review included only studies that provided quantitative evidence on the drivers and risks in humans from within the human reservoir and across the other two reservoirs. Descriptive studies were not included in this analysis, meaning evidence of risk factors from such studies was not captured, and comparison between quantitative and descriptive evidence could not be conducted

In conclusion, this systematic review provides an essential reference document upon which to assess the current state of risk factor studies for AR in humans over the past 10 years. Essentially, this review provides an indication as to the relative importance of risk factors as well as where information is lacking.

The added value of this study is that it emphasises the need for researchers to use standardised data collection protocols for observational studies aiming to report on AR risk factors in humans to increase the clarity with which risk factors are being captured. A simple framework utilising risk factor domains established in this review could enable a better representation of the underlying local level risks of AR in humans by increasing the granularity amongst the established risk being captured to improve our understanding of the risks of AR in humans. This framework could also be amended to enable health policy makers and funding bodies to allocate research funding towards setting specific factors which may contribute to the risk of AR in humans and in turn effectively prioritise resource allocation decisions to tackle AR. Thus by promoting alternative research agendas targeted towards a better understanding of underlying risks our understanding of the risks of AR may be altered. We hope that research agendas would benefit by moving away from convenient easy to produce studies to more exploratory studies hypothesizing the potential importance of the understudied areas arising from the community as clearly demonstrated in this review. These understudied areas may lead to further important factors which impact AR in humans, which may change our understanding of the transmission dynamics of AR in humans. This overview could be utilised to prioritise resources in terms of intervention choice and intervention evaluation, as well as direction of further research needs highlighted under recent AMR related funding initiatives.⁷³⁻⁷⁶.

Contributors

Anuja Chatterjee, Julie Robotham, Rifat Atun, Sara Boyd and Nichola Naylor were involved in the final study protocol development. Anuja Chatterjee carried out the literature search, independent review of all title abstracts and full texts, completed quality assessment, data analysis, result dissemination and manuscript write up. Maryam Modarai, Sara Boyd and Nichola Naylor were the three independent reviewers. Maryam Modarai checked at random the quality assessments conducted by Anuja Chatterjee. Julie Robotham and James Barlow were involved in the manuscript development and first draft. James Barlow, Nichola Naylor, Alison Holmes and Alan Johnson contributed to the final structure and content of the manuscript. The corresponding author and all co-authors contributed to the final version of the manuscript.

Declaration of Interests

All authors have completed the ICMJE uniform disclosure form and declare no competing interests relevant to the submitted work. SEB reports that outside of this work she receives research support from Roche Pharma, Allegra Therapeutics and Antabio. Outside of this work AHH has consulted for bioMérieux.

Acknowledgments

The authors would like to acknowledge Dr Ceire Costelloe for her suggestions and feedback during the protocol development and results analysis stages. The authors would also like to acknowledge the National Institute for Health Research Imperial Biomedical Research Centre and the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infection and Antimicrobial Resistance at Imperial College London, in partnership with Public Health England.

References

- 1 O'Neill J. Tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance. 2016.
- 2 Holmes AH, Moore LSP, Sundsfjord A, *et al.* Understanding the mechanisms and drivers of antimicrobial resistance. *Lancet* 2016; **387**: 176–87.
- 3 Marshall BM, Levy SB. Food animals and antimicrobials: Impacts on human health. *Clin Microbiol Rev* 2011; **24**: 718–33.
- 4 Robinson TP, Bu DP, Carrique-Mas J, *et al.* Antibiotic resistance is the quintessential One Health issue. *Trans R Soc Trop Med Hyg* 2016; **110**: 377–80.
- 5 Cabello FC, Godfrey HP, Buschmann AH, Dölz HJ. Aquaculture as yet another environmental gateway to the development and globalisation of antimicrobial resistance. *Lancet Infect Dis* 2016; **16**: e127-33.
- 6 Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. *BMC Infect Dis* 2014; **14**: 13.
- 7 Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. *BMJ* 2010; **340**: c2096.
- 8 McCullough AR, Rathbone J, Parekh S, Hoffmann TC, Del Mar CB. Not in my backyard: a systematic review of clinicians' knowledge and beliefs about antibiotic resistance. *J Antimicrob Chemother* 2015; **70**: 2465–73.
- 9 O'Neill J. Infection prevention, control and surveillance: Limiting the development & spread of drug resistance. 2016.
- 10 Allegranzi B. New IPC recommendations from WHO - the importance of IPC actions in fighting the AMR burden. 14 December 2016. 2016. www.who.int/gpsc/ipc-cc_slides.pdf?ua=1 (accessed July 3, 2017).
- 11 Department of Health. UK Five Year Antimicrobial Resistance Strategy 2013 to 2018. London, 2013.
- 12 Department of Health. Antimicrobial Resistance (AMR) Systems Map Antimicrobial Resistance (AMR) Systems. 2014.
- 13 Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P SL. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015; **4**.
- 14 Bryce A, Hay AD, Lane IF, Thornton H V, Wootton M, Costelloe C. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by *Escherichia coli* and association with routine use of antibiotics in primary care: systematic review and meta-analysis. *BMJ* 2016; **352**: i939.
- 15 Forbes HJ, Thomas SL, Smeeth L, *et al.* A systematic review and meta-analysis of risk factors for postherpetic neuralgia. *Pain* 2015; **157**: 30–54.
- 16 Higgins, Julian PT, and Sally Green eds. Cochrane handbook for systematic reviews of interventions. 2011.

- 649 17 Voor AF, Severin JA, Lesaffre EMEH, Vos MC. A systematic review and meta-Analyses show
650 that carbapenem use and medical devices are the leading risk factors for carbapenem-
651 resistant pseudomonas aeruginosa. *Antimicrob Agents Chemother* 2014; **58**: 2626–37.
- 652 18 Hendrik TC, Voor In 't Holt AF, Vos MC. Clinical and Molecular Epidemiology of Extended-
653 Spectrum Beta-Lactamase-Producing Klebsiella spp.: A Systematic Review and Meta-Analyses.
654 *PLoS One* 2015; **10**: e0140754.
- 655 19 McKinnell JA, Miller LG, Eells SJ, Cui E, Huang SS. A systematic literature review and meta-
656 analysis of factors associated with methicillin-resistant Staphylococcus aureus colonization at
657 time of hospital or intensive care unit admission. *Infect Control Hosp Epidemiol* 2013; **34**:
658 1077–86.
- 659 20 Lawton R, Mceachan RRC, Giles SJ, Sirriyeh R, Watt IS, Wright J. Development of an evidence-
660 based framework of factors contributing to patient safety incidents in hospital settings : a
661 systematic review. 2012. DOI:10.1136/bmjqs-2011-000443.
- 662 21 Pathirana T, Clark J, Moynihan R. Mapping the drivers of overdiagnosis to potential Thanya
663 Pathirana and colleagues explore strategies to tackle the problem of too much medicine.
664 2017; **3879**: 1–9.
- 665 22 Bouchard P, Carra MC, Boillot A, Mora F. Risk factors in periodontology : a conceptual
666 framework. 2017; : 125–31.
- 667 23 European Centre for Disease Prevention and Control, European Food Safety Authority,
668 European Medicines Agency. ECDC / EFSA / EMA first joint report on the integrated analysis of
669 the consumption of antimicrobial agents and occurrence of antimicrobial resistance in
670 bacteria from humans and food-producing animals 1 Joint Interagency Antimicrobial
671 Consumption and Resi. *EFSA J* 2015; **13**: 1–114.
- 672 24 van Cleef BA, Monnet DL, Voss A, Krziwanek K, Allerberger F, Struelens M et al. Livestock-
673 associated Methicillin-Resistant Staphylococcus aureus in Humans, Europe. *Emerg Infect Dis*
674 2011; **17**: 502–5.
- 675 25 European Food Safety Authority, Control EC for DP and C. The European Union summary
676 report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals
677 and food in 2014. *EFSA J* 2016; **14**. DOI:10.2903/j.efsa.2016.4380.
- 678 26 ECDC. Antimicrobial Resistance surveillance in Europe. 2015 DOI:10.2900/93403.
- 679 27 Nagy B, Szmolka A, Smole Možina S, et al. Virulence and antimicrobial resistance
680 determinants of verotoxigenic Escherichia coli (VTEC) and of multidrug-resistant E. coli from
681 foods of animal origin illegally imported to the EU by flight passengers. *Int J Food Microbiol*
682 2015; **209**: 52–9.
- 683 28 Kuenzli E, Jaeger VK, Frei R, et al. High colonization rates of extended-spectrum β -lactamase
684 (ESBL)-producing Escherichia coli in Swiss Travellers to South Asia– a prospective
685 observational multicentre cohort study looking at epidemiology, microbiology and risk factors.
686 *BMC Infect Dis* 2014; **14**: 528–37.
- 687 29 Jiang X, Yu T, Wu N, Meng H, Shi L. Detection of qnr, aac(6')-Ib-cr and qepA genes in
688 Escherichia coli isolated from cooked meat products in Henan, China. *Int J Food Microbiol*
689 2014; **187**: 22–5.
- 690 30 Canizalez-Roman A, Gonzalez-Nuñez E, Vidal JE, Flores-Villaseñor H, León-Sicairos N.
691 Prevalence and antibiotic resistance profiles of diarrheagenic *Escherichia coli* strains isolated
692 from food items in northwestern Mexico. *Int J Food Microbiol* 2013; **164**: 36–45.

693 31 Coleman BL, Salvadori MI, McGeer AJ, *et al.* The role of drinking water in the transmission of
694 antimicrobial-resistant *E. coli*. *Epidemiol Infect* 2012; **140**: 633–42.

695 32 Pollett S, Rocha C, Zerpa R, *et al.* Campylobacter antimicrobial resistance in Peru: a ten-year
696 observational study. *BMC Infect Dis* 2012; **12**: 193.

697 33 Rosengren Å, Fabricius A, Guss B, Sylvén S, Lindqvist R. Occurrence of foodborne pathogens
698 and characterization of *Staphylococcus aureus* in cheese produced on farm-dairies. *Int J Food*
699 *Microbiol* 2010; **144**: 263–9.

700 34 Presi P, Stärk KDC, Stephan R, Breidenbach E, Frey J, Regula G. Risk scoring for setting
701 priorities in a monitoring of antimicrobial resistance in meat and meat products. *Int J Food*
702 *Microbiol* 2009; **130**: 94–100.

703 35 Dambrosio A, Lorusso V, Quaglia NC, *et al.* *Escherichia coli* O26 in minced beef: Prevalence,
704 characterization and antimicrobial resistance pattern. *Int J Food Microbiol* 2007; **118**: 218–22.

705 36 Frye JG, Fedorka-Cray PJ. Prevalence, distribution and characterisation of ceftiofur resistance
706 in *Salmonella enterica* isolated from animals in the USA from 1999 to 2003. *Int J Antimicrob*
707 *Agents* 2007; **30**: 134–42.

708 37 Normanno G, La Salandra G, Dambrosio A, *et al.* Occurrence, characterization and
709 antimicrobial resistance of enterotoxigenic *Staphylococcus aureus* isolated from meat and
710 dairy products. *Int J Food Microbiol* 2007; **115**: 290–6.

711 38 Walsh C, Duffy G, O'Mahony R, Fanning S, Blair IS, McDowell DA. Antimicrobial resistance in
712 Irish isolates of verocytotoxigenic *Escherichia coli* (*E. coli*)-VTEC. *Int J Food Microbiol* 2006;
713 **109**: 173–8.

714 39 Messi P, Guerrieri E, De Niederhäusern S, Sabia C, Bondi M. Vancomycin-resistant enterococci
715 (VRE) in meat and environmental samples. *Int J Food Microbiol* 2006; **107**: 218–22.

716 40 Argudín MA, Mendoza MC, González-Hevia MA, Bances M, Guerra B, Rodicio MR. Genotypes,
717 exotoxin gene content, and antimicrobial resistance of *Staphylococcus aureus* strains
718 recovered from foods and food handlers. *Appl Environ Microbiol* 2012; **78**: 2930–5.

719 41 Hauser E, Tietze E, Helmuth R, *et al.* Pork contaminated with *Salmonella enterica* serovar
720 4,[5],12:i:-, an emerging health risk for humans. *Appl Environ Microbiol* 2010; **76**: 4601–10.

721 42 Slama K Ben, Jouini A, Sallem R Ben, *et al.* Prevalence of broad-spectrum cephalosporin-
722 resistant *Escherichia coli* isolates in food samples in Tunisia, and characterization of integrons
723 and antimicrobial resistance mechanisms implicated. *Int J Food Microbiol* 2010; **137**: 281–6.

724 43 Norström M, Hofshagen M, Stavnes T, Schau J, Lassen J, Kruse H. Antimicrobial resistance in
725 *Campylobacter jejuni* from humans and broilers in Norway. *Epidemiol Infect* 2006; **134**: 127–
726 30.

727 44 Leistner R, Meyer E, Gastmeier P, *et al.* Risk factors associated with the community-acquired
728 colonization of extended-spectrum beta-lactamase (ESBL) positive *Escherichia coli*. an
729 exploratory case-control study. *PLoS One* 2013; **8**: e74323.

730 45 Vandendriessche S, Vanderhaeghen W, Soares FV, *et al.* Prevalence, risk factors and genetic
731 diversity of methicillin-resistant *Staphylococcus aureus* carried by humans and animals across
732 livestock production sectors. *J Antimicrob Chemother* 2013; **68**: 1510–6.

733 46 Coleman BL, Louie M, Salvadori MI, *et al.* Contamination of Canadian private drinking water
734 sources with antimicrobial resistant *Escherichia coli*. *Water Res* 2013; **47**: 3026–36.

- 735 47 Alali WQ, Scott HM, Norby B. Assessing the similarity of antimicrobial resistance phenotypes
736 among fecal *Escherichia coli* isolates from two aggregated occupational cohorts of humans
737 versus swine using cluster analysis and multivariate statistics. *Prev Vet Med* 2010; **94**: 77–83.
- 738 48 Alali WQ, Scott HM, Christian KL, Fajt VR, Harvey RB, Lawhorn DB. Relationship between level
739 of antibiotic use and resistance among *Escherichia coli* isolates from integrated multi-site
740 cohorts of humans and swine. *Prev Vet Med* 2009; **90**: 160–7.
- 741 49 Köck R, Harlizius J, Bressan N, *et al.* Prevalence and molecular characteristics of methicillin-
742 resistant *Staphylococcus aureus* (MRSA) among pigs on German farms and import of
743 livestock-related MRSA into hospitals. *Eur J Clin Microbiol Infect Dis* 2009; **28**: 1375–82.
- 744 50 Price LB, Graham JP, Lackey LG, Roess A, Vailes R, Silbergeld E. Elevated risk of carrying
745 gentamicin-resistant *Escherichia coli* among U.S. poultry workers. *Environ Health Perspect*
746 2007; **115**: 1738–42.
- 747 51 Huijbers PMC, van Hoek AHAM, Graat EAM, *et al.* Methicillin-resistant *Staphylococcus aureus*
748 and extended-spectrum and AmpC β -lactamase-producing *Escherichia coli* in broilers and in
749 people living and/or working on organic broiler farms. *Vet Microbiol* 2015; **176**: 120–5.
- 750 52 Meyer E, Gastmeier P, Kola A, Schwab F. Pet animals and foreign travel are risk factors for
751 colonisation with extended-spectrum β -lactamase-producing *Escherichia coli*. *Infection* 2012;
752 **40**: 685–7.
- 753 53 Czekalski N, Sigdel R, Birtel J, Matthews B, Bürgmann H. Does human activity impact the
754 natural antibiotic resistance background? Abundance of antibiotic resistance genes in 21
755 Swiss lakes. *Environ Int* 2015; **81**: 45–55.
- 756 54 Machado A, Bordalo AA. Prevalence of antibiotic resistance in bacteria isolated from drinking
757 well water available in Guinea-Bissau (West Africa). *Ecotoxicol Environ Saf* 2014; **106**: 188–94.
- 758 55 Barkovskii AL, Bridges C. Persistence and profiles of tetracycline resistance genes in swine
759 farms and impact of operational practices on their occurrence in farms' vicinities. *Water Air*
760 *Soil Pollut* 2012; **223**: 49–62.
- 761 56 DeLorenzo ME, Thompson B, Cooper E, Moore J, Fulton MH. A long-term monitoring study of
762 chlorophyll, microbial contaminants, and pesticides in a coastal residential stormwater pond
763 and its adjacent tidal creek. *Environ Monit Assess* 2012; **184**: 343–59.
- 764 57 Akinyemi KO, Iwalokun BA, Foli F, Oshodi K, Coker AO. Prevalence of multiple drug resistance
765 and screening of enterotoxin (*stn*) gene in *Salmonella enterica* serovars from water sources in
766 Lagos, Nigeria. *Public Health* 2011; **125**: 65–71.
- 767 58 Sadowy E, Luczkiewicz A. Drug-resistant and hospital-associated *Enterococcus faecium* from
768 wastewater, riverine estuary and anthropogenically impacted marine catchment basin. *BMC*
769 *Microbiol* 2014; **14**: 66.
- 770 59 Waturangi DE, Wennars M, Suhartono MX, Wijaya YF. Edible ice in Jakarta, Indonesia, is
771 contaminated with multidrug-resistant *Vibrio cholerae* with virulence potential. *J Med*
772 *Microbiol* 2013; **62**: 352–9.
- 773 60 van Hoek AHAM, Veenman C, van Overbeek WM, Lynch G, de Roda Husman AM, Blaak H.
774 Prevalence and characterization of ESBL- and AmpC-producing Enterobacteriaceae on retail
775 vegetables. *Int J Food Microbiol* 2015; **204**: 1–8.
- 776 61 Arvaniti K, Lathyris D, Ruimy R, *et al.* The importance of colonization pressure in multiresistant
777 *Acinetobacter baumannii* acquisition in a Greek intensive care unit. *Crit Care* 2012; **16**: R102.

778 62 Tacconelli E, Cataldo MA, Paul M, *et al.* STROBE-AMS: recommendations to optimise reporting
779 of epidemiological studies on antimicrobial resistance and informing improvement in
780 antimicrobial stewardship. *BMJ Open* 2016; **6**: e010134.

781 63 Papadimitriou-Olivgeris M, Christofidou M, Fligou F, *et al.* The role of colonization pressure in
782 the dissemination of colistin or tigecycline resistant KPC-producing *Klebsiella pneumoniae* in
783 critically ill patients. *Infection* 2014; **42**: 883–90.

784 64 Hamel M, Zoutman D, O’Callaghan C. Exposure to hospital roommates as a risk factor for
785 health care-associated infection. *Am J Infect Control* 2010; **38**: 173–81.

786 65 Mitchell BG, Dancer SJ, Anderson M, Dehn E. Risk of organism acquisition from prior room
787 occupants: a systematic review and meta-analysis. *J Hosp Infect* 2015; **91**: 211–7.

788 66 Hobbs FDR, Bankhead C, Mukhtar T, *et al.* Clinical workload in UK primary care: a
789 retrospective analysis of 100 million consultations in England, 2007–14. *Lancet (London, England)* 2016; **387**: 2323–30.

791 67 Charani E, Castro-Sanchez E, Sevdalis N, *et al.* Understanding the determinants of
792 antimicrobial prescribing within hospitals: the role of ‘prescribing etiquette’. *Clin Infect Dis*
793 2013; **57**: 188–96.

794 68 Lin D, Ou Q, Lin J, Peng Y, Yao Z. A meta-analysis of the rates of *Staphylococcus aureus* and
795 methicillin-resistant *S aureus* contamination on the surfaces of environmental objects that
796 health care workers frequently touch. *Am J Infect Control* 2017; **45**: 421–9.

797 69 Flokas ME, Karageorgos SA, Detsis M, Alevizakos M, Mylonakis E. Vancomycin-resistant
798 enterococci colonisation, risk factors and risk for infection among hospitalised paediatric
799 patients: a systematic review and meta-analysis. *Int J Antimicrob Agents* 2017; **49**: 565–72.

800 70 See I, Wesson P, Gualandi N, *et al.* Socioeconomic Factors Explain Racial Disparities in Invasive
801 Community-Associated Methicillin-Resistant *Staphylococcus aureus* Disease Rates. *Clin Infect Dis*
802 2017; **64**: 597–604.

803 71 ECDC (European Centre for Disease Prevention and Control). European Centre for Disease
804 Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual Report
805 of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, 2014
806 DOI:10.2900/23549.

807 72 Hoelzer K, Wong N, Thomas J, Talkington K, Jungman E, Coukell A. Antimicrobial drug use in
808 food-producing animals and associated human health risks: what, and how strong, is the
809 evidence? *BMC Vet Res* 2017; **13**: 211.

810 73 Medical Research Council (MRC). Tackling AMR – A Cross Council Initiative. Accessed 10/2017.
811 2017. [https://www.mrc.ac.uk/research/initiatives/antimicrobial-resistance/tackling-amr-a-](https://www.mrc.ac.uk/research/initiatives/antimicrobial-resistance/tackling-amr-a-cross-council-initiative/)
812 [cross-council-initiative/](https://www.mrc.ac.uk/research/initiatives/antimicrobial-resistance/tackling-amr-a-cross-council-initiative/).

813 74 The Biotechnology and Biological Sciences Research Council (BBSRC). UK-China Antimicrobial
814 Resistance Initiative. Accessed 10/2017. 2017. [http://www.bbsrc.ac.uk/funding/filter/uk-](http://www.bbsrc.ac.uk/funding/filter/uk-china-antimicrobial-resistance-initiative/)
815 [china-antimicrobial-resistance-initiative/](http://www.bbsrc.ac.uk/funding/filter/uk-china-antimicrobial-resistance-initiative/).

816 75 Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). Joint Programming
817 Initiative on Antimicrobial Resistance. Accessed 10/2017. 2017. <http://www.jpiamr.eu/>.

818 76 The Center For Disease Dynamics, Economics & Policy (CDDEP). Global Antibiotic Resistance
819 Partnership. Accessed 10/2017. 2017. [https://cddep.org/partners/global-antibiotic-](https://cddep.org/partners/global-antibiotic-resistance-partnership/)
820 [resistance-partnership/](https://cddep.org/partners/global-antibiotic-resistance-partnership/).

821 77 Magiorakos A-P, Srinivasan A, Carey RB, *et al.* Multidrug-resistant, extensively drug-resistant
822 and pandrug-resistant bacteria: an international expert proposal for interim standard
823 definitions for acquired resistance. *Clin Microbiol Infect* 2012; **18**: 268–81.

824

825

826

827

828

829